Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Nippon Shinyaku Gets EU Orphan Tag for Myelofibrosis Med
August 9, 2023
- Otsuka Unit Astex, Merck Expand Drug Discovery Alliance
August 9, 2023
- Astellas Puts Up US$50 Million for CAR-T Player Poseida
August 9, 2023
- Astellas Set to Cut Development Time with Cell Culture Robot, Eyes 4 Billion Yen Profit per Product
August 9, 2023
- Shipment Restrictions Now Hit All Versions of Mounjaro in Japan
August 8, 2023
- Daiichi Sankyo to Shutter R&D Subsidiary in Tokyo in Group Rejig
August 8, 2023
- Iveric Bio’s AMD Drug Approved in US, Launch Set for This Month: Astellas
August 8, 2023
- Global PIII Study for Zipalertinib Begins for 1st Line NSCLC: Taiho
August 8, 2023
- Nippon Shinyaku’s DMD Therapy Gets Orphan Tag in US
August 8, 2023
- Kyowa Kirin Chief Admits Difficulties in Trial Design Felt with Dumped Kidney Disease Med
August 7, 2023
- Wakamoto Seeks to Add New Manufacturer for MaQaid amid Supply Woes
August 7, 2023
- Mitsubishi Tanabe Aims to Maximize Value of Mounjaro through Synergies with Other Products
August 4, 2023
- Kyowa Kirin’s 6-Month Sales Up 7.5% as Global Brands Log Positive Growth
August 4, 2023
- Rakuten Medical Gears Up for Global Pitch on Photoimmunotherapy: Chairman
August 4, 2023
- Lonsurf-Bevacizumab Snags US Approval for Colorectal Cancer: Taiho
August 4, 2023
- Opdivo Tops Japan Sales Ranking for 19 Months on End: Encise
August 4, 2023
- Eisai Sees Positive Shift in US Market for Leqembi after Full Approval: Exec
August 3, 2023
- Sumitomo to Focus on 3 Core Products in North America to Overcome Latuda Patent Cliff: President
August 3, 2023
- Mitsubishi Tanabe’s Q1 Sales Up 3.8% on Back of Bullish Oral Radicava Sales in US
August 3, 2023
- Pfizer’s Bivalent COVID Vaccines Approved for Primary Series in Japan
August 3, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…